Oncotelic Therapeutics Highlighted in BioMedWire Editorial for Next-Generation CNS Drug Delivery Platform

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) was featured in a BioMedWire editorial that examines the growing urgency around effective central nervous system (CNS) drug delivery. The editorial highlights Oncotelic's proprietary intranasal nose-to-brain (N2B) delivery platform, which is designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. This technology addresses a critical bottleneck in treating neurological disorders, where traditional drug delivery methods often fail due to the blood-brain barrier's protective function.

The editorial points to rising global Alzheimer's cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies. According to the World Health Organization, the number of people living with dementia is expected to rise from 55 million in 2020 to 78 million by 2030, underscoring the urgent need for effective treatments. Oncotelic's platform-based approach is part of a broader shift toward delivery innovation as a critical determinant of therapeutic success.

The coverage places Oncotelic alongside major biopharma and advanced therapeutics players, including Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Lunai Bioworks (NASDAQ: LNAI). This underscores continued momentum across next-generation treatment development. BioMedWire notes that Oncotelic's strategy combines platform scalability with monetization opportunities, including its agreement with Lunai involving defined applications for its N2B delivery technology. This model aims to address both commercial CNS indications and high-priority biodefense applications.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens its position in oncology and rare disease therapeutics.

For more information, visit the full press release at https://ibn.fm/wTLMS and stay updated with Oncotelic news at https://ibn.fm/OTLC.